Publications

Journal Article Research Support, Non-U.S. Gov't Ppublish 17 citations

PubMed: 36367091 DOI: 10.1042/CS20220235

Vascular dysfunction in COVID-19 patients: update on SARS-CoV-2 infection of endothelial cells and the role of long non-coding RNAs.

Clin Sci (Lond) 136(21):1571-1590

Authors: Jaroslav Pelisek, Benedikt Reutersberg, Urs F Greber, Alexander Zimmermann

Affiliations

  • Department of Vascular Surgery, University Hospital Zürich, Zürich, Switzerland.
  • Department of Molecular Life Sciences, University of Zürich, Switzerland.

Abstract

Although COVID-19 is primarily a respiratory disease, it may affect also the cardiovascular system. COVID-19 patients with cardiovascular disorder (CVD) develop a more severe disease course with a significantly higher mortality rate than non-CVD patients. A common denominator of CVD is the dysfunction of endothelial cells (ECs), increased vascular permeability, endothelial-to-mesenchymal transition, coagulation, and inflammation. It has been assumed that clinical complications in COVID-19 patients suffering from CVD are caused by SARS-CoV-2 infection of ECs through the angiotensin-converting enzyme 2 (ACE2) receptor and the cellular transmembrane protease serine 2 (TMPRSS2) and the consequent dysfunction of the infected vascular cells. Meanwhile, other factors associated with SARS-CoV-2 entry into the host cells have been described, including disintegrin and metalloproteinase domain-containing protein 17 (ADAM17), the C-type lectin CD209L or heparan sulfate proteoglycans (HSPG). Here, we discuss the current data about the putative entry of SARS-CoV-2 into endothelial and smooth muscle cells. Furthermore, we highlight the potential role of long non-coding RNAs (lncRNAs) affecting vascular permeability in CVD, a process that might exacerbate disease in COVID-19 patients.

MeSH

Infections, Lectins, C-Type, Sars Virus, Endothelial Cells, Heparan Sulfate Proteoglycans, Adam17 Protein, Angiotensin-Converting Enzyme 2, Covid-19, Sars-Cov-2

Cited by